Loading...
Market
Will there be changes in drug pricing regulations due to Shkreli's case by end of 2025?
2
Resolution / Starting Odds
New federal regulation • 25%
New state-level regulations • 25%
No regulatory change • 25%
Other changes • 25%
Legislative records or announcements from regulatory bodies
Story
Supreme Court Rejects 'Pharma Bro' Shkreli's Appeal Over $64.6M Penalty for 4,000% Drug Price Hike
Oct 7, 2024, 03:21 PM
The U.S. Supreme Court declined to hear former pharmaceutical executive Martin Shkreli's appeal against a $64.6 million financial penalty imposed by a judge. Shkreli, infamously known as the 'Pharma Bro', had raised the price of a life-saving drug by more than 4,000%, increasing the cost by over $700 per pill. He was penalized for blocking competition to the drug. The decision leaves in place the antitrust judgment against him.
View original story
Similar markets
Yes • 50%
No • 50%
Legislation passed • 25%
Non-binding resolution • 25%
No action taken • 25%
Other • 25%
Yes • 50%
No • 50%
No action taken • 25%
Recommendations for price reductions • 25%
Legislation introduced • 25%
Other • 25%
